Study of Sc-FOS for Pouchitis Prevention
- Conditions
- Pouchitis
- Interventions
- Drug: Short-Chain Fructooligosaccharide
- Registration Number
- NCT02203955
- Lead Sponsor
- Mayo Clinic
- Brief Summary
The main objective is to compare prebiotic therapy with placebo for the prevention of pouchitis after closure of diverting ileostomy in patients with an ileal pouch anal anastomosis. This study will also characterize the effects of prebiotics on the fecal microbiota and fecal microbial metabolites and correlate these effects with the primary outcome of development of pouchitis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 13
Not provided
- Crohn's disease.
- Perianal disease (including abscess, fissure, or stricture)
- Pregnancy
- Lactation
- Concurrent treatment for IBD or pouchitis
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Short-Chain Fructooligosaccharide Short-Chain Fructooligosaccharide 4 chews (8.0 g scFOS) orally per day for 12 months Maltodextrin Maltodextrin 4 chews (maltodextrin) daily for 12 months
- Primary Outcome Measures
Name Time Method Mean Change in Pouchitis Disease Activity Index (PDAI) at One Year baseline, 1 year In the PDAI, an overall score is calculated from three separate six-point scales comprising of clinical symptoms, endoscopic findings and histological changes. The PDAI incorporates histological features of acute inflammation, and establishes a cut-off of seven for differentiation between 'pouchitis (≥7 points) and 'no pouchitis' (\<7 points).
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Mayo Clinic in Rochester
🇺🇸Rochester, Minnesota, United States